Download PDF
Z Gastroenterol 2016; 54(02): 167-172
DOI: 10.1055/s-0041-111632
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

ASCO-Update 2015 – Neuigkeiten vom 51. Meeting der American Society of Clinical Oncology/ASCO 2015

ASCO-update 2015 – highlights of the 51. meeting of the american society of clinical oncology/ASCO 2015
S. Lorenzen
1   Medizinische Klinik, Klinikum rechts der Isar, München, Germany
,
D. Arnold
2   Internistische Onkologie, Klinik für Tumorbiologie, Freiburg, Germany
,
C. Fottner
3   Abteilung für Endokrinologie und Stoffwechselkrankheiten, Johannes Gutenberg-Universität, Mainz, Germany
,
J. Leichsenring
4   Abteilung für Hämatologie und Onkologie, Med. Klinik I, Ruhr-Universität Bochum, Germany
,
M. Moehler
5   I. Dept Medicine, Johannes Gutenberg University Hospital of Mainz, Germany
,
T. Seufferlein
6   Klinik für Innere Medizin I, Universitätsklinikum Ulm, Germany
,
A. Vogel
7   Klinik für Gastroenterologie, Hepatologie und Endokrinologie, MH-Hannover, Germany
,
M. M. Weber
3   Abteilung für Endokrinologie und Stoffwechselkrankheiten, Johannes Gutenberg-Universität, Mainz, Germany
,
A. Reinacher-Schick
4   Abteilung für Hämatologie und Onkologie, Med. Klinik I, Ruhr-Universität Bochum, Germany
› Author Affiliations
Further Information

Publication History

17 August 2015

17 December 2015

Publication Date:
08 February 2016 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das Gebiet der gastrointestinalen Onkologie entwickelt sich so rasch wie kaum ein anderes Feld, zum einen durch die Identifizierung neuer molekularer Targets und Therapieprinzipien, zum anderen durch die Etablierung und Verbesserung multimodaler Therapiekonzepte. Die nachfolgende Arbeit soll eine Zusammenfassung der wichtigsten Ergebnisse vom ASCO-Kongress 2015 zu den gastrointestinalen Tumoren liefern. Neben Studien zur perioperativen Therapie von Ösophagus-, Pankreas- und Kolonkarzinomen, werden erste beeindruckende Daten zu neuen Therapieansätzen wie der Immuntherapie beim Magenkarzinom, dem HCC und dem mikrosatelliteninstabilen Kolonkarzinom vorgestellt. Die Studien werden jeweils durch die Autoren gewertet.

Abstract

The field of gastrointestinal oncology is rapidly developing, on the one hand through the identification of novel molecular targets and therapeutic principles, on the other hand through the establishment and improvement of multidisciplinary treatment strategies. The following manuscript summarizes the most important trial results of the ASCO Meeting 2015 for gastrointestinal cancers. Besides trials on perioperative treatment of esophageal-, pancreatic- and colon cancer, we will present impressive data on new therapeutic strategies such as immunotherapy in gastric-, liver and microsatellite instable colorectal cancer. The trials will be put into context by the authors.

Schlüsselwörter

Ösophaguskarzinom - Magenkarzinom - kolorektales Karzinom - Pankreaskarzinom - Leberzellkarzinom - NET

Key words

esophageal cancer - gastric cancer - colorectal cancer - pancreatic cancer - hepatobiliary cancer - neuroendocrine tumors
 

  • Literatur

  • 1 Alderson D, Langley RE, Nankivell MG et al. Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). J Clin Oncol 2015; 33 (suppl ; abstr 4002)
    PubMedGoogle Scholar
  • 2 Pauligk C, Tannapfel A, Meiler J et al. Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO. J Clin Oncol 2015; 33 (suppl; abstr 4016)
    PubMedGoogle Scholar
  • 3 Homann N, Pauligk C, Luley K et al. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer 2012; 130: 1706-1713
    CrossrefPubMedGoogle Scholar
  • 4 Lorenzen S, Thuss-Patience P, Al-Batran SE et al. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol 2013; 24: 2068-2073
    CrossrefPubMedGoogle Scholar
  • 5 Hofheinz RD, Hegewisch-Becker S, Thuss-Patience PC et al. HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group. J Clin Oncol 2014; 32: 5s (suppl; abstr 4073)
    CrossrefPubMedGoogle Scholar
  • 6 Cunningham D, Tebbutt NC, Davidenko I et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol 2015; 33: (suppl; abstr 4000)
    PubMedGoogle Scholar
  • 7 Shah MA, Bang YJ, Lordick F et al. METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). J Clin Oncol 2015; 33: (suppl; abstr 4012)
    PubMedGoogle Scholar
  • 8 Pavlakis N, Sjoquist KM, Tsobanis E et al. INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG) — Final overall and subgroup results. J Clin Oncol 2015; 33 (suppl; abstr 4003)
    PubMedGoogle Scholar
  • 9 Bang YJ, Chung HC, Shankaran V et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J Clin Oncol 2015; 33: (suppl; abstr 4001)
    PubMedGoogle Scholar
  • 10 Sinn M, Liersch T, Gellert K et al. CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks – A prospective randomized phase III study. J Clin Oncol 2015; 33 (suppl. abstr. 4007)
    PubMedGoogle Scholar
  • 11 Hingorani SR, Harris WP, Hendifar AE et al. High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study. J Clin Oncol 2015; 33 (suppl. abstr. 4006)
    PubMedGoogle Scholar
  • 12 Dasari A, Phan AT, Caplin ME. CLARINET Study Group et al. Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged <65 vs. >65 years: Subgroup analyses from the CLARINET study. J Clin Oncol 2015; 33 (suppl. abstr. e15177)
    PubMedGoogle Scholar
  • 13 Kulke MH et al. A Randomized Open-label Phase II Study of Everolimus Alone or in Combination with Pasireotide LAR in Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): COOPERATE-2 Trial.
    PubMedGoogle Scholar
  • 14 Pavel ME, Lombard-Bohas C, Van Cutsem E et al. Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias. J Clin Oncol 2015; 33: (suppl; abstr 4091)
    PubMedGoogle Scholar
  • 15 Yao JC, Guthrie K, Moran C et al. SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). J Clin Oncol 2015; 33: (suppl; abstr 4004)
    PubMedGoogle Scholar
  • 16 Kulke MH, Niedzwiecki D, Foster NR et al. Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). J Clin Oncol 2015; 33: (suppl; abstr 4005)
    PubMedGoogle Scholar
  • 17 Hobday TJ, Yin J, Pettinger A et al. Multicenter prospective phase II trial of bevacizumab (bev) for progressive pancreatic neuroendocrine tumor (PNET). J Clin Oncol 2015; 33: (suppl; abstr 4096)
    PubMedGoogle Scholar
  • 18 Zhu A, Baron AD, Malfertheiner P et al. Ramucirumab as Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of REACH Results by Child-Pugh Score. J Clin Oncol 2015; 33: (suppl; abstr 4108)
    PubMedGoogle Scholar
  • 19 Vogel A, Kasper S, Weichert W et al. Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced KRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2015; 33: (suppl; abstr 4082)
    PubMedGoogle Scholar
  • 20 El-Khoueiry AB, Melero I, Crocenzi TS et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015; 33: (suppl; abstr LBA101)
    PubMedGoogle Scholar
  • 21 Duffy AG, Makarova-Rusher OV, Kerkar SP et al. A pilot study of tremelimumab – a monoclonal antibody against CTLA-4 – in combination with either trans catheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2015; 33: (suppl; abstr 4081)
    PubMedGoogle Scholar
  • 22 Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch repair deficiency. J Clin Oncol 2015; 33: (suppl; abstr LBA100)
    PubMedGoogle Scholar
  • 23 Zaanan A, Shi Q, Taieb J et al. Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX ± cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials. J Clin Oncol 2015; 33: (suppl; abstr 3506)
    PubMedGoogle Scholar
  • 24 Taieb J, Le Malicot K, Penault-Llorca FM et al. Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX ± cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials. J Clin Oncol 2015; 33: (suppl; abstr 3507)
    PubMedGoogle Scholar
  • 25 Giannakis M, Shukla S, Mu SX et al. Comprehensive molecular characterization of colorectal cancer reveals genomic predictors of immune cell infiltrates. J Clin Oncol 2015; 33: (suppl;abstr 3505)
    PubMedGoogle Scholar
  • 26 Meyers BM, Al-Shamsi HO, Figueredo AT. Cochrane systematic review and meta-analysis of adjuvant therapy for stage II colon cancer. J Clin Oncol 2015; 33: (suppl; abstr 3513)
    PubMedGoogle Scholar
  • 27 Iveson T, Kerr R, Saunders MP et al. Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy. J Clin Oncol 2015; 33: (suppl; abstr 3514)
    PubMedGoogle Scholar
  • 28 Hamaguchi T, Shimada Y, Mizusawa J et al. Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine (cape) in patients with stage III colon cancer (CC): Results of Japan Clinical Oncology Group study (JCOG0910). J Clin Oncol 2015; 33: (suppl; abstr 3512)
    PubMedGoogle Scholar
  • 29 Ruers T, Punt CJA, van Coevorden F et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004. J Clin Oncol 2015; 33: (suppl; abstr 3501) (CLOCC)
    PubMedGoogle Scholar
  • 30 Gibbs P, Heinemann V, Sharma NK et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2015; 33: (suppl; abstr 3502)
    PubMedGoogle Scholar
  • 31 Siena S, Sartore-Bianchi A, Lonardi S et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol 2015; 33: (suppl; abstr 3508)
    PubMedGoogle Scholar
  • 32 Hong DS, Van Morris K, El Osta BE et al. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol 2015; 33: (suppl; abstr 3511)
    PubMedGoogle Scholar
  • 33 Le DT, Uram JN, Wang H et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. 2015; 372: 2509-2520 DOI: 10.1056/NEJMoa1500596.
    PubMedGoogle Scholar